These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 32370596)

  • 1.
    Walsh RE; Lannan M; Wen Y; Wang X; Moreland CA; Willency J; Knierman MD; Spindler L; Liu L; Zeng W; Rocha GV; Obungu V; Lu J; Kaliyaperumal A; Ferrante A; Siegel R; Malherbe LP
    MAbs; 2020; 12(1):1764829. PubMed ID: 32370596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical immunogenicity risk assessment of biotherapeutics using CD4 T cell assays.
    Walsh RE; Nix A; Ackaert C; Mazy A; Schockaert J; Pattyn S; Malherbe L
    Front Immunol; 2024; 15():1406040. PubMed ID: 38863708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Internalization of therapeutic antibodies into dendritic cells as a risk factor for immunogenicity.
    Siegel M; Bolender AL; Ducret A; Fraidling J; Hartman K; Looney CM; Rohr O; Hickling TP; Kettenberger H; Lechmann M; Marban-Doran C; Kraft TE
    Front Immunol; 2024; 15():1406643. PubMed ID: 39263220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Secukinumab, a novel anti-IL-17A antibody, shows low immunogenicity potential in human in vitro assays comparable to other marketed biotherapeutics with low clinical immunogenicity.
    Karle A; Spindeldreher S; Kolbinger F
    MAbs; 2016; 8(3):536-50. PubMed ID: 26817498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aggregation of human recombinant monoclonal antibodies influences the capacity of dendritic cells to stimulate adaptive T-cell responses in vitro.
    Rombach-Riegraf V; Karle AC; Wolf B; Sordé L; Koepke S; Gottlieb S; Krieg J; Djidja MC; Baban A; Spindeldreher S; Koulov AV; Kiessling A
    PLoS One; 2014; 9(1):e86322. PubMed ID: 24466023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumour necrosis factor-alpha chimeric antibody (infliximab) inhibits activation of skin-homing CD4+ and CD8+ T lymphocytes and impairs dendritic cell function.
    Bedini C; Nasorri F; Girolomoni G; Pità Od; Cavani A
    Br J Dermatol; 2007 Aug; 157(2):249-58. PubMed ID: 17489975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonantigen specific CD8+ T suppressor lymphocytes originate from CD8+CD28- T cells and inhibit both T-cell proliferation and CTL function.
    Filaci G; Fravega M; Negrini S; Procopio F; Fenoglio D; Rizzi M; Brenci S; Contini P; Olive D; Ghio M; Setti M; Accolla RS; Puppo F; Indiveri F
    Hum Immunol; 2004 Feb; 65(2):142-56. PubMed ID: 14969769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of MHC class I presentation of exogenous antigen by dendritic cells is controlled by CD4+ T cells engaging class II molecules in cholesterol-rich domains.
    Machy P; Serre K; Baillet M; Leserman L
    J Immunol; 2002 Feb; 168(3):1172-80. PubMed ID: 11801652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contribution of enhanced engagement of antigen presentation machinery to the clinical immunogenicity of a human interleukin (IL)-21 receptor-blocking therapeutic antibody.
    Xue L; Hickling T; Song R; Nowak J; Rup B
    Clin Exp Immunol; 2016 Jan; 183(1):102-13. PubMed ID: 26400440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery.
    Schnurr M; Chen Q; Shin A; Chen W; Toy T; Jenderek C; Green S; Miloradovic L; Drane D; Davis ID; Villadangos J; Shortman K; Maraskovsky E; Cebon J
    Blood; 2005 Mar; 105(6):2465-72. PubMed ID: 15546948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor-specific CD4+ T cells are activated by "cross-dressed" dendritic cells presenting peptide-MHC class II complexes acquired from cell-based cancer vaccines.
    Dolan BP; Gibbs KD; Ostrand-Rosenberg S
    J Immunol; 2006 Feb; 176(3):1447-55. PubMed ID: 16424172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional Specialty of CD40 and Dendritic Cell Surface Lectins for Exogenous Antigen Presentation to CD8(+) and CD4(+) T Cells.
    Yin W; Gorvel L; Zurawski S; Li D; Ni L; Duluc D; Upchurch K; Kim J; Gu C; Ouedraogo R; Wang Z; Xue Y; Joo H; Gorvel JP; Zurawski G; Oh S
    EBioMedicine; 2016 Mar; 5():46-58. PubMed ID: 27077111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficient and versatile manipulation of the peripheral CD4+ T-cell compartment by antigen targeting to DNGR-1/CLEC9A.
    Joffre OP; Sancho D; Zelenay S; Keller AM; Reis e Sousa C
    Eur J Immunol; 2010 May; 40(5):1255-65. PubMed ID: 20333625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dendritic cell maturation enhances CD8+ T-cell responses to exogenous antigen via a proteasome-independent mechanism of major histocompatibility complex class I loading.
    Robson NC; Beacock-Sharp H; Donachie AM; Mowat AM
    Immunology; 2003 Jul; 109(3):374-83. PubMed ID: 12807483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The presence of interleukin-27 during monocyte-derived dendritic cell differentiation promotes improved antigen processing and stimulation of T cells.
    Jung JY; Roberts LL; Robinson CM
    Immunology; 2015 Apr; 144(4):649-60. PubMed ID: 25346485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of maturation and activation of human dendritic cells: a mechanism underlying the beneficial effect of Viscum album as complimentary therapy in cancer.
    Elluru SR; Duong van Huyen JP; Delignat S; Kazatchkine MD; Friboulet A; Kaveri SV; Bayry J
    BMC Cancer; 2008 Jun; 8():161. PubMed ID: 18533025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficient presentation of known HLA class II-restricted MAGE-A3 epitopes by dendritic cells electroporated with messenger RNA encoding an invariant chain with genetic exchange of class II-associated invariant chain peptide.
    Bonehill A; Heirman C; Tuyaerts S; Michiels A; Zhang Y; van der Bruggen P; Thielemans K
    Cancer Res; 2003 Sep; 63(17):5587-94. PubMed ID: 14500399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and characterization of dendritic cell internalization and activation assays contributing to the immunogenicity risk evaluation of biotherapeutics.
    Siegel M; Padamsey A; Bolender AL; Hargreaves P; Fraidling J; Ducret A; Hartman K; Looney CM; Bertinetti-Lapatki C; Rohr O; Hickling TP; Kraft TE; Marban-Doran C
    Front Immunol; 2024; 15():1406804. PubMed ID: 39229274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tremelimumab (anti-CTLA4) mediates immune responses mainly by direct activation of T effector cells rather than by affecting T regulatory cells.
    Khan S; Burt DJ; Ralph C; Thistlethwaite FC; Hawkins RE; Elkord E
    Clin Immunol; 2011 Jan; 138(1):85-96. PubMed ID: 21056008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stroma-dependent development of two dendritic-like cell types with distinct antigen presenting capability.
    Periasamy P; O'Neill HC
    Exp Hematol; 2013 Mar; 41(3):281-92. PubMed ID: 23178375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.